Nasdaq:BKYI
BIO KEY INTERNATIONAL INC
A medical imaging technology firm delivering specialized software solutions to global healthcare networks with a strong R&D pipeline.
Key Metrics
Investment Thesis
Bull Case
Investors might consider BIO KEY if they believe the narrowing net loss trend signals an eventual return to profitability once current legacy liabilities are managed or new product cycles launch. The company's substantial investment in R&D combined with proprietary software assets suggests strong long-term potential for capturing market share in the growing telemedicine and remote diagnostics sectors. A turnaround story could offer significant upside if management successfully executes cost reduction initiatives and improves cash conversion ratios in the next fiscal year.
Bear Case
The stock faces severe bearish pressure due to four consecutive years of negative net income and a massive accumulated deficit that outweighs current tangible assets. Operating cash flows are consistently negative, forcing the company to rely on financing activities to sustain operations rather than generating internal capital for growth. With total liabilities nearly matching total assets and limited liquid cash relative to operating burn rates, the risk of dilution through new equity issuance or asset impairment is high.
About BIO KEY INTERNATIONAL INC
BIO KEY INTERNATIONAL INC. specializes in providing advanced medical imaging solutions and related software services to healthcare providers globally. The company serves hospitals, clinics, and independent imaging centers with proprietary technology designed to enhance diagnostic accuracy and operational efficiency. Recent financials indicate a focus on maintaining market share through strategic investments in research and development despite current profitability challenges.
Analysis
Management Discussion
Management demonstrated an ability to stabilize revenue at nearly $7 million after a slight dip from 2023 levels, though the company continues to report substantial net losses narrowing from -$11.9M in 2022 to -$4.3M in 2024. Cash flow from operations turned negative while financing activities provided significant inflows, suggesting reliance on external capital to fund working capital changes and ongoing operational expenses. Despite investing over $2.5 million in R&D and maintaining a robust cash reserve of $437k, the path to consistent profitability remains uncertain given the widening gap between revenue and operating costs.
Industry Overview
The global medical imaging industry is experiencing rapid expansion driven by aging demographics, increasing disease prevalence, and the shift toward digital health records and AI-assisted diagnostics. Competition is intensifying as large tech firms enter the space with integrated software platforms, while traditional hardware manufacturers face pressure to innovate faster than ever before. Companies that can offer comprehensive, cloud-ready solutions with strong cybersecurity features are better positioned to retain enterprise customers in this volatile landscape.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $7.0M | $7.8M | $6.9M |
| Cost of Revenue | $2.4M | $6.3M | $1.3M |
| Gross Profit | $4.6M | $1.4M | $5.6M |
| Operating Expenses | $14.5M | $10.3M | $9.7M |
| Operating Income | $-9.9M | $-8.8M | $-4.0M |
| R&D | $3.3M | $2.4M | $2.5M |
| G&A | $9.4M | $7.9M | $7.1M |
| Stock-Based Comp | $387.9K | $265.7K | $243.2K |
| D&A | — | $75.1K | $93.0K |
| Depreciation | $43.8K | $75.1K | $93.0K |
| Amortization | $298.1K | $354.6K | $305.0K |
| Other OpEx | $1.9M | $0 | $0 |
| Non-Operating Income | $-2.0M | $170.5K | $-312.6K |
| Interest Expense | $10.5K | $218.3K | — |
| Interest Income | $233 | $11.5K | $110 |
| Pre-Tax Income | $-11.9M | $-8.7M | $-4.3M |
| Income Tax | $20.4K | $-134.0K | $-23.0K |
| Continuing Ops | $-12.0M | $-8.5M | $-4.3M |
| Discontinued Ops | $40.9K | $0 | $0 |
| Net Income | $-11.9M | $-8.5M | $-4.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-11.9M | $-8.5M | $-4.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $9.0M | $2.6M | $1.9M |
| Cash & Equivalents | $2.6M | $511.4K | $437.6K |
| Accounts Receivable | $1.5M | $1.2M | $718.2K |
| Inventory | $4.4M | $445.7K | $378.3K |
| Prepaid Expenses | $342.7K | $364.2K | $278.6K |
| Other Current Assets | $49.5K | $99.3K | $74.2K |
| Long-Term Assets | $2.4M | $1.9M | $6.7M |
| PP&E (Net) | $107.4K | $220.2K | $140.2K |
| Intangibles | $1.8M | $1.4M | $1.1M |
| Goodwill | $0 | — | — |
| Operating Leases | $197.4K | $36.9K | $73.4K |
| LT Investments | — | — | $5.0M |
| Other LT Assets | $291.8K | $229.8K | $417.4K |
| Total Assets | $11.3M | $4.5M | $8.6M |
| Current Liabilities | $5.5M | $3.2M | $4.6M |
| Accounts Payable | $1.1M | $1.3M | $818.2K |
| Current Debt | $120.0K | $138.7K | — |
| Current Leases | $159.7K | $37.8K | $24.6K |
| Deferred Revenue | $462.4K | $415.0K | $773.3K |
| Other Current Liab | $2.6M | $0 | $1.7M |
| Long-Term Liabilities | $587.0K | $240.1K | $290.0K |
| Long-Term Debt | $326.8K | $188.8K | $44.8K |
| LT Operating Leases | $37.8K | $0 | $49.0K |
| Other LT Liab | $170.3K | $23.0K | $0 |
| Total Liabilities | $6.0M | $3.5M | $4.8M |
| Shareholders' Equity | $5.3M | $1.1M | $3.8M |
| Paid-In Capital | $122.0M | $126.0M | $133.0M |
| Retained Earnings | $-116.5M | $-125.0M | $-129.3M |
| AOCI | $-242.6K | $22.8K | $49.3K |
| Total L&E | $11.3M | $4.5M | $8.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-11.9M | $-8.5M | $-4.3M |
| Non-Cash Adjustments | $5.3M | $4.7M | $2.5M |
| Working Capital Changes | $401.2K | $69.8K | $-1.1M |
| Cash from Operations | $-6.2M | $-3.8M | $-2.9M |
| Capital Expenditures | $82.0K | $1.0K | $13.0K |
| Cash from Investing | $-696.6K | $-1.0K | $-13.0K |
| Cash from Financing | $1.9M | $1.4M | $2.8M |
| FX Effect | $-96.1K | $236.9K | $26.5K |
| Net Change in Cash | $-5.1M | $-2.1M | $-73.8K |
| Beginning Cash | $7.8M | $2.6M | $511.4K |
| Ending Cash | $2.6M | $511.4K | $437.6K |
Frequently Asked Questions
How does BIO KEY INTERNATIONAL INC make money?
The company's revenue is primarily derived from the sale and licensing of proprietary medical imaging hardware and advanced post-processing software packages. Additional streams include subscription-based maintenance contracts, technical support services, and custom development projects for specific hospital systems. Current financials suggest a significant portion of revenue comes from continuing operations focused on core product lines in radiology and cardiology markets.
What are the main risks for BKYI?
Persistent negative net income and operating profit indicate ongoing operational inefficiencies or high cost structures that could erode shareholder value if not addressed. The company carries a significant retained earnings deficit exceeding $129 million, which may limit future flexibility for acquisitions or share buybacks without external capital injection. Heavy reliance on current liabilities relative to cash reserves suggests potential liquidity pressure if revenue growth stalls or accounts receivable collection slows. Regulatory changes in medical device approval processes or pricing pressures from payers could further compress margins in a competitive market environment.
What is BKYI's competitive advantage?
BIO KEY leverages deep proprietary technology in image reconstruction algorithms that provide superior diagnostic clarity compared to generic alternatives. The company benefits from established long-term relationships with major hospital networks, creating high switching costs for customers due to integrated workflow systems. A dedicated internal R&D team allows for rapid iteration of software features that adapt quickly to emerging clinical needs and regulatory changes.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.